Natera, Inc. (NTRA)
NASDAQ: NTRA · IEX Real-Time Price · USD
95.01
+2.13 (2.29%)
May 1, 2024, 9:49 AM EDT - Market open
Natera Employees
Natera had 3,293 employees on December 31, 2023. The number of employees increased by 275 or 9.11% compared to the previous year.
Employees
3,293
Change (1Y)
275
Growth (1Y)
9.11%
Revenue / Employee
$328,749
Profits / Employee
-$132,038
Market Cap
11.33B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3,293 | 275 | 9.11% |
Dec 31, 2022 | 3,018 | 348 | 13.03% |
Dec 31, 2021 | 2,670 | 855 | 47.11% |
Dec 31, 2020 | 1,815 | 776 | 74.69% |
Dec 31, 2019 | 1,039 | 64 | 6.56% |
Dec 31, 2018 | 975 | 82 | 9.18% |
Dec 31, 2017 | 893 | 41 | 4.81% |
Dec 31, 2016 | 852 | 136 | 18.99% |
Dec 31, 2015 | 716 | 42 | 6.23% |
Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tenet Healthcare | 106,500 |
Universal Health Services | 96,700 |
Charles River Laboratories International | 21,800 |
Smith & Nephew | 19,081 |
Bruker | 9,707 |
Exact Sciences | 6,600 |
Incyte | 2,524 |
Sarepta Therapeutics | 1,314 |
NTRA News
- 2 hours ago - Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage - Business Wire
- 9 days ago - Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications - Business Wire
- 20 days ago - Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation - Business Wire
- 23 days ago - Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients - Business Wire
- 26 days ago - Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer - Business Wire
- 4 weeks ago - Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer - Business Wire
- 6 weeks ago - Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer - Business Wire
- 6 weeks ago - New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease - Business Wire